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AbstrAct
Our understanding of oncogenic signaling pathways has strongly fostered current 
concepts for targeted therapies in metastatic colorectal cancer. The RALA pathway 
is novel candidate due to its independent role in controlling expression of genes 
downstream of RAS. 
We compared RALA GTPase activities in three colorectal cancer cell lines by 
GTPase pull-down assay and analyzed the transcriptional and phenotypic effects of 
transient RALA silencing. Knocking-down RALA expression strongly diminished the 
active GTP-bound form of the protein. Proliferation of KRAS mutated cell lines was 
significantly reduced, while BRAF mutated cells were mostly unaffected. By microarray 
analysis we identified common genes showing altered expression upon RALA silencing 
in all cell lines. None of these genes were affected when the RAF/MAPK or PI3K 
pathways were blocked. 
To investigate the potential clinical relevance of the RALA pathway and its 
associated transcriptome, we performed a meta-analysis interrogating progression-
free survival of colorectal cancer patients of five independent data sets using Cox 
regression. In each dataset, the RALA-responsive signature correlated with worse 
outcome.
In summary, we uncovered the impact of the RAL signal transduction on 
genetic program and growth control in KRAS- and BRAF-mutated colorectal cells 
and demonstrated prognostic potential of the pathway-responsive gene signature in 
cancer patients.
INtrODUctION
With nearly 800,000 new cases each year, colon 
cancer is the second most common malignancy in 
the world. Since several years, targeted therapies 
directed against receptor tyrosine kinases (RTK) as key 
components of the cellular signaling system are in clinical 
use. The NCCN guidelines (http://www.nccn.org, version 
1.2014) list bevacizumab, cetuximab or panitumumab in 
combination with 5-fluorouracil chemotherapy as initial 
therapy option for advanced or metastatic disease. The 
therapeutic antibodies panitumumab and cetuximab can 
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even be initially used as single agents in patients not 
eligible for combination therapy. RTK signals converge 
on RAS proteins, which serve as central molecular 
switches for intracellular communication and control of 
gene expression. Activating mutations in the KRAS gene 
are highly prevalent in colorectal and other cancers [1]. 
Therapeutic strategies targeting mutant RAS proteins 
directly have either failed in the clinic [2] or are still in 
early development [3]. In colorectal tumor patients, the 
mutational status of the KRAS isoform of the RAS gene 
family permits to roughly discriminate antibody therapy 
responders from non-responders. Therapies usually fail 
in KRAS-mutated tumors, while therapeutic benefit is 
observed in approx. one fifth of KRAS-wild-type tumors 
[4]. There is growing evidence showing that alternate 
mutations not affecting KRAS itself may also preclude 
efficient antibody therapy. Consequently, detailed patient 
stratification considering further critical elements of the 
RTK/RAS signaling system is likely to be essential, as is 
a detailed characterization of their impact on cytoplasmic 
signaling and gene expression control [5, 6]. 
The epidermal growth factor receptor (EGFR)/RAS 
signaling system regulates cellular proliferation, energy 
metabolism, survival and architecture, migration and 
angiogenesis via cytoplasmic effectors and transcriptional 
targets (for review see: [7]). Activated RAS proteins 
communicate with three major downstream effector 
pathways, the RAS-RAF-MAPK, the phosphoinositide 
3-kinase (PI3K)-AKT and the RALGDS/RALA/B 
pathways [8]. Considerable efforts have been made to 
assign the individual branches of the signaling system 
downstream of RAS to specific phenotypic properties 
[9]. For example, the RAF pathway was linked to 
proliferation [10], apoptosis [11], energy metabolism [12] 
and angiogenesis. The PI3K pathway was associated with 
overlapping functions such as cell proliferation [13], and 
evasion of apoptosis [14] as well as with specific functions 
such as macrophage recruitment [15]. The RALGDS/RAL 
pathway composed of two small GTP-binding proteins 
RALA and RALB contributes to proliferation, anchorage 
independent growth [16], tumorigenicity [17], migration 
and metastasis [18, 19]. Moreover, the RALA pathway 
is known to stimulate metastasis of RAS transformed 
fibroblasts in vitro and in vivo [18]. In KRAS mutated 
human pancreatic carcinoma cells RALA is found to be 
necessary for anchorage-independent growth in vitro and 
for tumor growth in vivo [17]. In mouse models of KRAS 
mutated prostate cancer, RALB is shown to mediate 
tumor growth, cell migration and bone metastasis in vivo 
[20]. In colorectal cancer cells, the RALA and RALB 
pathways show antagonistic roles in regulating anchorage-
independent growth [16].
Major efforts are underway to design inhibitors to 
block the RAF/MAPK and PI3K/AKT pathways and to use 
anti-MAPK and anti-PI3K drugs in clinical trials [21, 22, 
23]. In contrast, the RAL pathway has not been targeted 
in a comparable manner [24]. In view of the functional 
relevance of the RAS/RAL pathway, further investigations 
on its contribution to cancer cell phenotypes and the 
deregulation of the transcriptome are warranted. Finding 
out if the RAL branch of the RAS signaling system 
impinges on distinct pathway targets or simultaneously on 
genes responsive to MAPK or PI3K pathways [25, 26] is 
of central importance for understanding its global function 
and for evaluating its relevance for cancer therapy. 
In view of the role of RALA in RAS-induced 
tumorigenesis in human cells [27] and particularly its 
involvement in colorectal cancer [28], we investigated 
the role of RALA in colorectal cancer cell lines carrying 
KRAS mutations in codon 12, 13 or the BRAF V600E 
mutation. We silenced RALA expression by RNA 
interference, investigated the effect on cellular phenotypes 
and contrasted RALA-dependent transcriptional profiles 
with MAPK and PI3K-dependent ones. In addition, we 
studied the prognostic potential of RAL-pathway targets 
by performing a meta-analysis of publicly available 
microarray-based expression profiles of colorectal cancer 
patients with documented clinical outcomes. 
rEsULts
rALA activity and rAL pathway-mediated 
phenotypic effects in colorectal cancer cell lines 
harboring different driver mutations
RALA activity, as measured by GTP-binding, was 
highest in SW480 cells, harboring mutated KRAS G12V 
and in HCT116 cells harboring the GGC to GAC mutation 
in KRAS codon 13. RALA activity was also detectable in 
HT29 colorectal cancer cells, which are KRAS wild-type 
and carry a BRAF V600E mutation (Figure 1A). Transient 
silencing by siRNA reduced RALA mRNA expression 
from 77% (HCT116) to 95% (HT29) compared to both 
mock and scrambled siRNA transfection controls (Figure 
1B). Reduced RALA expression resulted in strongly 
reduced GTP-binding in all three cell lines (Figure 1C).
Next we analyzed the impact of RALA silencing 
on anchorage-dependent and independent growth of 
the colorectal cancer cells. The proliferation of the two 
KRAS mutated cell lines was significantly reduced in 
both culture systems as compared to controls (Figure 2). 
BRAF mutated HT29 cells did not show any significant 
growth reduction following treatment with RALA siRNA. 
However, cell cycle analysis of HT-29 cells showed a 
slight increase in the sub-G1 peak on DNA histograms 
(Supplementary Figure 1), suggesting that the RALA 
pathway plays a minor role in cell survival. The migratory 
potential determined by scratch assays was highest in 
HCT116 cells as compared to SW480 and HT29 cells. 
Knock-down of RALA had no significant effect, indicating 
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Figure 1: A. RAL and RAS activity assays using lysates obtained from SW480 (KRAS mutation in codon 12), HCT116 (codon 13) and 
HT29 (KRAS wild-type, BRAFV600E mutation) cells (+: positive control; -: negative control). b. TaqMan RT-PCR analysis of RALA 
mRNA levels in the same cells following RALA knock-down using siRNA described by [27] and controls (p < 0.05). (C) RALA activity 
assay following knock-down (SC: scramble siRNA transfected control, KD: RALA knockdown, M: mock - transfection reagents only).
Figure 2: Effects of the anchorage-dependent A. and anchorage-independent b. growth of SW480, HCT116 and HT29 cells 48 h after 
treatment with scrambled siRNA-duplex (S), transfection reagents only (M) and RALA specific siRNA (R) determined by colorimetric 
XTT assays. The values were normalized in percent to S and the differences to S were calculated. Mean +/- SEM of three independent 
biological experiments with three technical replicas each is shown. *p ≤ 0.05; ***p ≤ 0.001. 
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that this pathway does not significantly modulate cell 
migration under the conditions used for the three cell lines 
(results not shown).
Pathway-restricted patterns of gene expression
We have previously established pathway-specific 
gene expression signatures for MAPK and PIK3CA, 
suggesting a modular response of the transcriptome to 
oncogenic pathway activation [25, 26]. Since the RAL 
pathway is another important downstream branch of 
the RAS signaling system, we reasoned that there also 
exists a RAL-pathway responsive signature [9]. To 
confirm the impact of active KRAS on the activity of 
the RAL pathway, we silenced KRAS expression in the 
three colorectal cell lines. A direct link between KRAS 
and RALA activity was demonstrated in HCT116 cells, 
whereas RALA activity was not impaired in SW480 and 
HT29 cell lines after KRAS knockdown (Figure 3). This 
suggests that RALA activation is independent on upstream 
KRAS signaling in these two cell lines.
To determine the impact of the RALA pathway on 
gene expression, we interrogated Affymetrix microarrays 
using RNA prepared from cell lines, in which RALA 
expression was transiently silenced. Cells treated with 
scrambled siRNA were used as controls. Normalized gene 
expression for each sample are available in Supplemental 
Table 2. We compared the RALA pathway-dependent 
expression profiles with MAPK-and PI3K-regulated gene 
sets identified previously [25, 26]. Hierarchical clustering 
of the 20 top genes regulated by the RALA, MAPK or 
PI3K pathways revealed a significant difference between 
the pathway-restricted gene sets, particularly when 
Figure 3: Effects of KrAs signaling on rALA and rALb expression and activity. Western blot after KRAS siRNA A. and 
Western blot after pull-down b.. siCtl: control siRNA; siPool: set of four KRAS siRNAs (Dharmacon). Raf1: substrate of KRAS pull-down 
and RalBP1: substrates for RALA pull-down.
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considering marked differences between the individual cell 
lines (Figure 4A). Altogether, 613 genes were regulated by 
the RAL pathway (see Supplemental Table 3.). Of the RAL 
pathway-target genes, 89.7% were distinct from MAPK- 
and PI3K-pathway responsive targets (Figure 4B). Hence, 
the RALA pathway-responsive gene signature identified 
in the three colorectal cancer cell lines comprises 554 
genes, irrespective of the mutational status of KRAS or 
BRAF. The list of these 554 genes regulated by the RAL 
pathway only is depicted in Supplemental Table 4. The 
genes encoding the inter-alpha-trypsin inhibitor heavy 
chain 5 (ITIH5), contactin-associated protein-like 2 
(CNTNAP2), trafficking Protein particle complex subunit 
6A (TRAPPC6A) and lipocalin-2 (LCN2) were the only 
ones commonly regulated by RAL, PI3K and RAF/MAPK 
pathways. 
correlation between the rALA signature and 
clinical outcome
In view of the previously investigated role of 
RAL signaling in proliferation and malignant properties 
of cancer cells, we analyzed the correlation of RAL 
pathway-regulated genes with progression-free survival of 
colorectal cancer patients. We retrieved five independent 
datasets, in which gene expression profiles of tumors and 
clinical follow-up of patients were documented (Table 
1). Patient tumors characterized by a higher expression 
of the RALA signature had a shorter relapse-free 
survival in each dataset (GSE41258: HR = 2, p = 0.044; 
Figure 4: rAL pathway-restricted gene expression in colorectal cancer cell lines. A. Euclidean distance clustering of 20 top 
genes (having the lowest p value in the class comparison) responding to one of the three pathways (total number  =  60). Clustering indicates 
that the similarity of the pathway-responsive target gene pattern exceeds the differences between cell lines. b. Venn diagram showing the 
overall number of genes up-regulated and down-regulated due to inhibition of the MAPK, PI3K and RAL pathway, respectively, in three 
colorectal cancer cell lines. The MAPK pathway was inhibited by treating cells with the MEK inhibitor U0126, the PI3K pathway with 
LY294002 and the RAL pathway with a specific siRNA. Quality control of microarray data is summarized in Supplemental Table 1. The 
complete normalized dataset including all cell line arrays is available in Supplemental Table 2. The list of 613 genes regulated by the RAL-
pathway is depicted in Supplemental Table 3. The list of 554 genes regulated by the RAL pathway only is listed in Supplemental Table 4. 
The raw data is accessible in GEO by the accession number GSE39857.
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GSE1433: HR = 5.5, p = 0.0013; GSE17538: HR = 5.1, 
p = 0.00058; GSE37892: HR = 2, p = 0.032; GSE39582: 
HR = 1.7, p = 0.00088). At the same time, the expression 
signature derived using the MEK inhibitor UO126 was 
not significant, and the signature established by the PI3K 
inhibitor LY2904 was only significant in three out of five 
dataset (GSE17538: HR = 2.7, p = 0.0097; GSE14333: 
HR = 2.5, p = 0.0074; GSE39582: HR = 1.8, p = 0.00048). 
Kaplan-Meier survival plots for the RALA signature in 
each dataset are displayed in Figure 5.
One of the RALA pathway dependent transcriptional 
targets, IQGAP1, encodes a multifunctional scaffold 
protein that interacts with various signaling proteins 
including MAP kinases. RAL pathway-dependent 
regulation of IQGAP1 potentially enables a feedback 
between RALA and MAPK signaling [29]. To support this 
link, we have validated the effect of RALA inhibition on 
IQGAP1 expression (Figure 6).
Colon cancer subtype classification including the 
chromosomal instable (colon cancer subtype 1 – CSS1), 
the microsatellite-instable (CSS2) and the sessile-
serrated adenoma subtype (CSS3) was available for 326 
patients for two datasets as published previously [30]. 
Of the genes included in the RALA signature, 31% had 
highest expression in the CSS1 subtype, 29% had highest 
expression in the CSS2 subtype and 40% had highest 
expression in the CSS3 subtype. There was no significant 
association between RALA signature and colon cancer 
molecular subtypes.
Figure 5: Kaplan-Meier survival plots derived by employing the signature of RALA responsive genes in five independent 
colon cancer datasets shows worse prognosis for those patients where a higher expression of rALA signature was 
observed. 
table 1: Datasets used in the independent clinical validation of the rALA signature.
GEO dataset 
ID GEO platform ID
samples with 
rFs Mean follow-up (months) reference
GSE14333 GPL570 255 43.5 [48]
GSE17538 GPL570 164 47.2 [49]
GSE37892 GPL570 130 41.8 [50]
GSE39582 GPL570 560 48.6 [51]
GSE41258 GPL96 118 66.4 [52]
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DIscUssION
The RALA pathway is robustly active in colorectal 
cancer cell lines harboring KRAS or BRAF driver 
mutations. Silencing of RALA expression resulted in 
growth reduction of KRAS-mutated SW40 and HCT116 
cells, but not in BRAF-mutated HT-29 cells. This suggests 
that the RAL pathway contributed to the proliferative 
potential of cells, in which effector activation is triggered 
by GTP-bound KRAS proteins. Diminishing GTPase 
activity by RALA knock-down in HT-29 cells had no 
significant effect on proliferation supporting the notion 
that proliferation is mainly triggered by RAF/MAPK 
signaling. The migratory potential of these colorectal 
cancer cell lines was not affected by knocking-down 
RALA expression in contrast to other types of cancer cells 
[31]. This suggests that the migratory potential requires 
mechanisms controlled by other effector pathways.
Gene expression profiling of RALA pathway-
depleted cells permitted identification of specific 
transcriptional targets. Overall, we recovered 554 genes 
responding to the RAL pathway but not to the RAF/MAPK 
and PI3K pathways. This finding supports the notion that 
the overall transcriptional response triggered by the RTK/
RAS signaling system is delimited by individual effector 
pathways downstream of RAS and is essentially modular 
[32]. Surprisingly, we uncovered a large overlap of RAL 
pathway-responsive genes in the cell lines regardless of 
the expressed driver mutation in KRAS or BRAF. In the 
absence of mutated KRAS, the RAL pathway is likely to 
be indirectly activated by wild-type RAS proteins. It is 
well known that the RAF pathway stimulates expression of 
Figure 6: Effect of the rALA inhibitor bQU57. A. on mRNA expression of IQGAP1 and CD24 in SW480 cells b.
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heparin-binding epidermal growth factor (HB-EGF) [33], 
which may then activate all downstream effector pathways 
via RAS as the central switch. The feedback from RAF 
to EGFR [34, 35] provides a mechanistic explanation for 
RALA activation caused by upstream alterations in EGFR 
or RAF genes. 
We used RALA specific target genes that were 
commonly deregulated in all three cell lines for analysis 
of their correlation with progression-free survival in five 
independent colorectal cancer datasets involving 1,227 
colorectal cancer patients, for whom data on relapse-free 
survival were reported. Using this strategy we were able 
to robustly uncover the correlation between survival and 
the RALA signature. Importantly, when compared to 
PI3K and MEK inhibition, the RALA signature was the 
only one significantly correlated to survival in each of the 
investigated datasets. Our results support the function of 
the RALA pathway as an additional collateral pathway 
further driving tumor progression. This suggest the 
potential of future therapeutic applications blocking the 
RALA pathway in addition to suppression of other effector 
pathways downstream of RAS, e.g. in patients receiving 
systemic therapies targeting RAF, ERK or PI3K.
The overall complexity of the RALA pathway-
related signature requires further analysis of individual 
target genes in a systematic way in order to elucidate 
their functional contribution to cellular phenotypes and 
clinical features. Notably, there is growing evidence for 
cross-talk with other critical signaling pathways [36]. The 
down-regulation of the IQGAP1 gene encoding IQ motif 
containing GTPase activating protein homologue 1 upon 
RALA inhibition provides a likely example for an indirect 
interaction via transcriptional regulation and implies the 
RALA signaling pathway as an upstream regulator of 
MAPK signaling. The IQGAP protein family comprises 
three scaffold proteins, of which IQGAP1 is best 
characterized and known to interact with RAF, MEK and 
ERK and to be up-regulated in cancer [37]. In addition, 
IQGAP1 was shown to be correlated with invasion and 
poor prognosis [38]. Mice deficient in IQGAP were 
refractory to HRAS-driven carcinogenesis and depletion 
of IQGAP1 reduced invasion in RAS oncogene-driven 
cancer cells by suppression of ERK activity [29]. The 
interaction of ERK and IQGAP1, which is mediated via 
the WW domain of the scaffold, has emerged as a novel 
therapeutic target [37]. Moreover, in addition to the 
MAPK pathway IQGAP1 may modulate other oncogenic 
pathways by binding to E-cadherin and beta-catenin [39] 
and by regulating the activation state of Rho A/Rho C to 
promote breast cancer cell proliferation and migration 
[40].
Three independent colon cancer subtypes have 
been recently identified: the first subtype (CSS1) includes 
chromosomal-instable tumors, the second subtype include 
microsatellite-instable cancer, and tumors in the third 
subtype exhibit a very unfavorable prognosis and are 
refractory to epidermal growth factor receptor-targeted 
therapy [30]. Our results support the independence of 
the RALA pathway from the molecular subtypes thereby 
emphasizing the importance of RALA as an independent 
factor in colon cancer pathogenesis.
In conclusion, the RALA pathway impinges on 
the transcription of a distinct subset of target genes in 
colorectal cancer cells independent of the KRAS and 
BRAF mutational status. RALA pathway-responsive genes 
were unaffected by RAF/MAPK and PI3K signaling. In 
view of the correlation of RAL pathway-responsive genes 
and patient survival, further exploitation of therapeutic 
approaches [17] involving monotherapy as well as 
combinatorial therapies against non-mutated signaling 
proteins [41] are warranted.
MAtErIALs AND MEtHODs 
cell culture
The colorectal cancer cell lines SW480, HCT116 
and HT29 obtained from the ATCC. The cell lines 
were maintained at 37oC and 5% CO2 in a humidified 
incubator in D10-medium containing DMEM (Invitrogen) 
supplemented with 10% fetal bovine serum (Sigma-
Aldrich), 2 mM ultraglutamine (Lonza, BioWhittaker), 
and 100 units/ml penicillin/streptomycin (Biochrom AG).
KrAs and rALA activation assay
The activation states of KRAS and RALA proteins 
were analyzed by using GTPase Pull-down and Detection 
kits (RAL: STA-408-CB and pan-RAS: STA-400-CB) 
based on specific downstream effectors fused to GST, 
which bind to the active form of GTPases (Cell Biolabs). 
Cell protein lysates (500 µg) were incubated with 50 
µl glutathione resin and GST protein binding domains 
for 1h to capture active small GTPases according to 
the manufacturer`s protocol. After washing, the bound 
GTPase was recovered by eluting the GST-fusion protein 
from the glutathione resin. The purified GTPase was 
detected by Western blot using specific antibodies supplied 
in the kit. Positive and negative controls were generated 
using GTPγS (0.1 mM) and GDP (1 mM) (Thermo Fisher 
Scientific). 
transient transfections
One day before transfection 3 × 105 HCT116 and 
SW480 as well as 1.5 × 105 HT29 cells were plated in 
10 cm dishes (BD Falcon) with D10-medium. SiRNA 
transfections were done twice in 24 h-intervals using 
Lipofectamine RNAiMAX (Invitrogen) for HT29 and 
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HCT116 cell lines and Lipofectamine 2000 (Invitrogen) 
for SW480 cells according to the manufacturer’s 
specifications. The following oligonucleotides were 
used to synthesize siRNAs using the Silencer® siRNA 
Construction Kit (Applied Biosystems) according 
to manufacturer’s specifications: RalA siRNA (1) 
: sense sequence: 5’-AGACAGGTTTCTGTAG 
AAGACCTGTCTC-3’; antisense sequence: 
5’-AACAGAGCTGAGCAGTGGAATCCTGTCTC-3’ 
[27]. RalA siRNA (2): sense sequence 
5’-AACTAAGATA TCGATCTGGACCCTGTCTC-3´, 
antisense sequence: 5’-AAGTCCAGATCGATA 
TCTTAGCCTGTCTC-3’; non-targeted scrambled 
oligonucleotide for SW480 cells: sense sequence: 
5’-AACGCGAGCTCGTGCGAGGGTCCTGTCTC-3’, 
antisense sequence: 
5’-AAACCCTCGCACGAGCTCCGCCCTGTCTC-3’. 
Synthesized siRNAs were transfected at a final 
concentration of 1.5 nM. We used an alternative scrambled 
siRNA control for HT29 and HCT116 cells lines (silencer 
negative control no.1, AM4611, Applied Biosystems) at 
a final concentration of 60 nM. In addition, cells were 
transfected with transfection reagents only (Mock control). 
For KRAS knockdown we used On-target KRAS siRNA 
LQ-0050069-00-0005 purchased from Dharmacon 
(Lafayette, CO, USA). 
Inhibition of rALA by bQU57 
The RALA inhibitor BQU57 [42] was purchased 
from Apexbio Ltd (Boston, USA). BQU57 was used in 
concentrations of 1 µM, 3 µM and 10 µM for 24 hours. 
To measure the effect of RALA inhibition on IQGAP1, 
RT-PCR was performed using the forward primer 
5’-GCCAAGATGTATCTACTGTATCC-3’ and the 
reverse primer 3’-TCTGTGAAGTCAACCTTTCC-5’. 
The established RALA target CD24 [43] was used 
as internal control. For CD24, the forward primer 
5’-CTACCCACGCAGATTTATTCC-3’ and reverse 
primer 3’-TGGCATTAGTTGGATTTGGG-5’ were used 
in RT-PCR.
rNA isolation, cDNA synthesis and quantitative 
real-time rt-Pcr analysis
Total RNA isolation and purification was 
performed using Qiagen RNeasy Mini Kit with 
QIAshredder according to the manufacturer’s protocol. 
RNA concentration and integrity were analyzed 
spectrophotometrically with a NanoPhotometer (Implen) 
at a wavelength of 260 nm and 280 nm, respectively. RNA 
purity was assessed by determining the ratio of OD260/ 
OD280 and was within the range of 1.8 to 2.0.
cDNA synthesis was performed with 50 ng/
µl of total RNA per sample using TaqMan® Reverse 
Transcription Reagents (Applied Biosystems) in a Techne 
Progene Thermal Cycler according to the manufacturer’s 
protocol. Real-time RT-PCR reactions were performed 
in a StepOnePlus Real Time PCR System (Applied 
Biosystems) using TaqMan Gene Expression Master 
Mix (Applied Biosystems). Micro Amp Fast Optical 96-
Well Reaction Plates and the following TaqMan gene 
expression assays were used: RALA (HS00800233_S1), 
UBE2D2 (HS003666152_m1) as endogenous control 
for HCT116 cells and Beta-actin (HS9999903_m1) as 
endogenous control for SW480 and HT29 cell lines. 
Relative transcript levels were determined by calculating 
2deltaCt values.
Proliferation assays
Cell proliferation was monitored semi-quantitatively 
in a sodium 3’ [1-( phenylyamino-carbonyl)-3, 
4-tetrazolium]-bis-(4-methoxy-6-nitro)-benzene sulfonic 
acid hydrate (XTT)-based colorimetric assay using the 
cell proliferation kit II (Roche). To estimate anchorage-
dependent and anchorage-independent growth, 5000 
cells/well were seeded into untreated 96-well plates (BD 
Falcon) in a volume of 150 μl medium or into poly-HEMA 
coated 96-well plates, respectively. For the preparation of 
poly-HEMA coated 96-well plates, 100 υl of a 5 mg/ml 
stock solution of poly-HEMA (Sigma-Aldrich) dissolved 
in 96% ethanol by mixing at room temperature for 4 h were 
added to the wells and allowed to dry for 72 h at 37oC. 
Growth of cells was determined in triplicate experiments 
48 h after the transient knock-down. Formazan formation 
was determined spectrophotometrically. The optical 
density of the medium without cells was subtracted from 
all probe values to obtain the final results. The statistical 
significance was calculated using ANOVA and Tukey’s 
post hoc tests.
sDs-Page and western blotting
Protein concentration was measured by staining 
with amido black assay (Merck) according to the 
manufacturer’s specifications. Per sample, 50 μg of 
proteins and 5 µl of PageRuler Prestained Protein 
Ladder (SM0671, Fermentas) were fractionated by 
electrophoresis through 12% SDS-polyacrylamide gels 
(SDS-PAGE) and transferred to Protran nitrocellulose 
membranes (Whatman) by semi-dry blotting using Tris-
base, Glycerol, (Merck), 10 % SDS, methanol (J.T.Baker, 
The Netherlands) in double-distilled water for 30 min 
with a constant current at 100 mA per membrane. The 
membranes were blocked with 5% non-fat dry milk 
(AppliChem GmbH) in TBST (Tris-buffered saline 
(TBS) + 0.05% Tween®-20, Serva) or with 3% BSA in 
TBST (Sigma-Aldrich, München). For the detection of 
active RAL and RAS proteins, we used the following 
Oncotarget13343www.impactjournals.com/oncotarget
primary mouse monoclonal antibodies: RALA included 
in STA-408-CB and pan-RAS included in STA-400-CB 
pull-down assays, RALB: #3523, KRAS: #2146 and beta-
tubulin: #TA801672 (Cell Signaling). Anti-mouse IgG-
Horseradish Peroxidase (HRP)-conjugate (1:5000 dilution, 
325-035-045, Dianova) or anti-rabbit IgG-HRP-conjugate 
(1:10, 000 dilution; 7074, Cell Signaling) were used as 
secondary antibody. Protein bands were visualized using 
the ECL chemoluminescence detection system (GE Health 
Care) on X-ray films (Amersham Hyperfilm e).
scratch assays
To distinguish between migration and cell 
proliferation, we performed experiments with serum 
reduced medium (FCS concentrations between 0.1%-1%). 
The optimal FCS concentrations for migration assays were 
determined by XTT assays. Cells ceased proliferation 29 
h after reduction of FCS concentrations 0.1% for SW480 
and HT29 cells as well as to 0.5% for HCT116 cells. Prior 
to the scratch assay, cells were transiently transfected 
twice with siRNA in 10 cm dishes (BD Falcon). One day 
after the second transfection, 5 x 105 HT29 cells, 2.1 x 
105 HCT116 cells or 6.7 x 105 SW480 cells were plated 
into 12-well plates (BD Falcon) containing medium with 
10% FCS. Under these conditions, the cells attached to 
form confluent monolayers. Then, cells were washed with 
serum-free medium to remove residual FCS and media 
with reduced serum were added.. The monolayers were 
wounded 29 h later by scratching cells off the dish using 
a 100 µl plastic pipette tip for HCT116 and HT29 cells 
and 10 µl plastic tips for SW480 cells. To remove non-
adherent cells, the wound was gently washed with serum 
free medium. Cell migration was documented using a 
digital microscope (Keyence BZ-8000, Keyence) at 40-
fold magnification after defined time intervals for up 
to 96 h after wounding. The wound area in pixels was 
determined using ImageJ software (http://rsweb.nih.gov/
ij/). The quantification was calculated using the following 
formula: (area of fresh wound - area after x hours) / x 
hours  =  pixels/hour.
cell cycle analysis
Trypsinized cells were denatured in cold 70 
% ethanol overnight, pelleted by centrifugation and 
resuspended in PBS supplemented with 0.1 % TritonX 
/ 0.5 % BSA and incubated with 10 mg/ml RNase at 
37°C for 30 min. After centrifugation, the pellet was 
resuspended in dilution buffer and incubated with 20 µg/
ml propidium iodide at room temperature in the dark for 
20 min. DNA histograms were recorded in a FACSCalibur 
flow cytometer (BD Biosciences). The raw data were 
analyzed with the programs Cylchred and WinMDI 2.8 
(Joseph Trotter, San Diego, USA).
Whole genome transcriptome analysis 
Transcriptional profiles were obtained by 
interrogating human whole genome arrays U133 2.0 
(Affymetrix Inc.) with total RNA isolated 48 h after RALA 
siRNA transfer. To compare the RAL pathway-dependent 
profiles with those regulated by MAPK- and PI3K-
signaling, we used raw expression data of GSE18232 and 
GSE18005 [25, 26] deposited in GEO. 
The microarrays were MAS 5.0 normalized in the 
R statistical environment (http://www.R-project.org) using 
the Bioconductor package Affy (http://www.bioconductor.
org). MAS 5.0 performed as one of the best among 
various normalization methods when using RT-PCR-
based validation measurements of microarray data [44]. 
To eliminate the effects of different instrument -default 
settings for average expression on the GPL96 and GPL570 
platforms, a second scaling normalization was performed 
on the matched gene set to adjust the average expression 
of each array to 1,000. Our data can be accessed in GEO 
using the accession number GSE39857. 
As basic quality assessment of the Affymetrix 
microarrays, we measured the eight parameters according 
to the Affymetrix Whitepapers (http://www.affymetrix.
com/support/technical/whitepapers.affx). We tested their 
method using an extended version of our previously 
published database [45]. The distribution of the arrays 
was assessed and outliers were identified as those having 
a parameter value outside of the range of 95% of samples. 
Detailed results for each sample are listed in Supplemental 
Table 1. For probe set quality control, we used Jetset 
[46], a tool that allows assessment of each probe set for 
specificity, splice isoform coverage, and robustness against 
transcript degradation.
Feature selection and clustering
Normalized gene expression data were imported 
into BRB-ArrayTools 3.8.1 (developed by Dr. Richard 
Simon and Amy Peng Lam, http://linus.nci.nih.gov/BRB-
ArrayTools.html). Intensity thresholding at the minimum 
value was performed, if the spot intensity was below the 
minimum value of 10. If less than 20 % of expression data 
had at least a 1.5 -fold change in either direction from 
the gene’s median value or the percent of data missing 
or filtered out exceeded 50%, the gene was discarded. 
Altogether 19, 961 probe sets passed the filtering criteria. 
Finally, probe sets with a median expression below 500 
(MAS 5.0 unit) were excluded from the analysis.
In the next step, class comparison using paired t-test 
was performed to compare treated and control cell lines. 
Only probe sets with a minimum fold change of 2 between 
the two investigated groups were included. Finally, genes 
differentially expressed in the control samples (scrambled 
siRNA transfection and mock transfection, respectively) 
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were excluded from the list of regulated genes. The 
significance threshold was set to 0.05. 
Hierarchical clustering was performed using the 
Genesis software (http://genome.tugraz.at/genesisclient/
genesisclient_description.shtml). In all analyses, average 
linkage clustering was computed for the experiments and 
genes. For visualization, the gene expression values were 
centered on the mean for each gene. 
GEO search for colon cancer samples
Colon cancer gene expression datasets with survival 
were identified in GEO using the search keywords 
“colon”, “cancer”, “gpl96”, and “gpl570” (http://www.
ncbi.nlm.nih.gov/geo/). Only publications with available 
raw data, clinical survival information, and containing at 
least 100 patients were included. We considered only data 
obtained with Affymetrix HG-U133A (GPL96) and HG-
U133 Plus 2.0 (GPL570) microarrays, because of their 
frequent application and the common representation of 
22,277 probe sets. 
Meta-analysis of the colon cancer datasets
The raw .CEL files were processed as described 
above. The mean expression of all genes having a 
significance below 0.01 in siRNA-treated cells was 
designated as a RALA-signature. The package “survival” 
was used to calculate and plot Kaplan-Meier survival 
curves, hazard ratio (and 95% confidence intervals) 
and logrank P in each dataset separately as described 
previously [47]. The same analysis was also performed 
using the previously published PI3K and MEK signatures 
[25, 26].
To assess the correlations between RALA regulated 
genes and colon cancer subtypes, we used the samples in 
the clinical database according to their assignment to colon 
cancer subtypes as described in the original publication 
[30]. The correlation of all RALA target genes with 
colorectal cancer subtypes was assessed by comparing the 
number of genes showing the highest expression in each 
subtype by a chi-square test. Significance was set at p < 
0.01.
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